P93 | Hypereosinophilic syndrome and novel eosinophil-depleting therapies
Year: 2025
Type: article
Study design: Case Report
Abstract: Premises: Hypereosinophilic syndrome (HES) is a rare systemic inflammatory disorder characterized by an elevated eosinophil count and a heterogeneous clinical presentation. Conventional treatments may have significant dose-limiting side effects, but novel therapies targeting eosinophils may offer a more favourable efficacy and safety profile, in particular, mepolizumab, a monoclonal antibody neutralizing interleukin 5 (IL-5) and commonly used at a dosage of 100 mg for treating severe asthma, has recently been approved for HES at a dosage of 300 mg every 4 weeks.Description of the Case report: An 83 yrs old patient with history of asthma and mild eosinophilia, was admitted for fatigue, arthromyalgia, and peripheral neuropathy, associated with hypereosinophilia (21.000/µL) and >20% eosinophilic infiltration in bone marrow. Extensive diagnostic tests (including bone marrow biopsy, cytogenetics, molecular testing for BCR-ABL and major rearrangements) ruled-out major organ involvement, infections, malignancies, and myeloproliferative diseases. Diagnosed with HES, the patient was treated with prednisone (25-50 mg QD), followed by subcutaneous mepolizumab (300 mg every 4 weeks), resulting in symptom resolution and prolonged steroid-sparing effects.Conclusions: IL-5 targeted therapy resulted in decreased eosinophil counts, preventing relapses within 6 months, and reducing prednisone to <5 mg QD, minimizing long-term systemic corticosteroid side effects. Mepolizumab showcased efficacy in HES, offering a promising treatment with potential long-term benefits.
Source: Italian Journal of Medicine
Authors: Vo Van Kha, Tran Thi Huong Ly, Pham Thi Thanh Hoa, Vo Huynh Nhu, Damas Hendriansyah, Nusratuddin Abdullah, Rudy B. Leonardy, Mardiah Tahir, Samrichard Rambulangi, Firdaus Hamid, Filomena Pietrantonio, Vera Kopsaj, Francesco Rosiello, Aurora Tomassoni, Luca Moriconi, Donatella Padua, Kiki Rizki Amelia, Efendi Lukas, Nurbani Bangsawan, Isharyah Sunarno, Retno Budiarti Farid, Sriwijaya Qadar, Rabab H. Elshaikh, Ashok Kumar Sah, Abdelrahman Mohamed Abukanna, Abdulrahman Algarni, Ammar Abdelmola, Hussam Ali Osman, Tagwa Yousif Elsayed Yousif, Elryah I. Ali, Hiba Ali, Ayman Hussein Alfeel, Thanh Long Nguyen, Victor Storm, Lam Toi Phung, Cong Thien Le, Thi Thu Ha Le, Thi Hoa Nguyen, Son Tung Vu, Thien Thang Tran, Minh Hanh Vu, Van Tuan Nguyen, Francesco Ventrella, Anna Belfiore, Antonio Greco, Franco Mastroianni, Salvatore Lenti, Domenico Ruggiero, Michele Cannone, Vincenzo Ostilio Palmieri, Massimo Errico, Giuseppe Mancia, Guido Grassi, Sverre E. Kjeldsen
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4413685228